Unaudited Financial Statement For The Half-Year Ended 30Th September 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Godavari Drugs Ltd reported its Q2 FY26 and H1 FY26 results, showing a mixed picture. Revenue from operations for Q2 stood at Rs. 2,664.94 lakhs, marginally up from Rs. 2,608.79 lakhs in Q2 last year, but H1 FY26 revenue declined ~13.4% YoY to Rs. 5,046.07 lakhs (vs Rs. 5,829.54 lakhs in H1 FY25). Net profit for H1 FY26 fell ~25% to Rs. 204.13 lakhs (vs Rs. 271.94 lakhs), with H1 EPS at Rs. 2.71 vs Rs. 3.61 earlier. Profit before tax for H1 came in at Rs. 242.36 lakhs, down from Rs. 326.42 lakhs. The statutory auditor (Ayyadevara & Co.) issued a clean limited review report with no qualifications, and no exceptional items were disclosed.
The double-digit drop in half-yearly revenue and profits signals weak top-line momentum and margin pressure, which is negative for near-term investor sentiment. However, sequential recovery in Q2 and a clean audit report limit the downside narrative.